Peptide Library

FDA-approved

Hormones & metabolism

Pasireotide

Evidence

FDA approved

Class

Somatostatin analog

/

Pasireotide

KEY TAKEAWAY

Pasireotide is a synthetic cyclic peptide that binds several somatostatin receptor subtypes. It is sold as Signifor. The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.

Written by the Veylo editorial team · Updated

November 2026

At a glance

At a glance

What it is

Somatostatin analog

Approved for

Cushing's disease and acromegaly

Key fact

The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.

Route

Subcutaneous injection, or a monthly injection into muscle

Evidence strength

FDA approved

What it is

What it is

Pasireotide is a synthetic cyclic peptide that binds several somatostatin receptor subtypes. It is sold as Signifor.

How it works

How it works

It lowers the release of ACTH and growth hormone from pituitary tumors.

Regulatory status

Regulatory status

The FDA approved pasireotide (Signifor) in 2012 for Cushing's disease, and a long-acting form (Signifor LAR) in 2014 for acromegaly.

What it is used for

What it is used for

Cushing's disease and acromegaly.

Side effects and risks

Side effects and risks

High blood sugar is very common and can be significant. Gallstones, diarrhea and a slow heart rate are also reported.

Citations

Citations

U.S. FDA prescribing information for Pasireotide. DailyMed, National Library of Medicine.

Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.

Veylo

Clinician-guided peptide care, paired with baseline blood testing and ongoing support.

Peptides referenced on this site are compounded medications and are investigational; they have not been approved by the FDA for the uses described. Nothing here is medical advice. Prescriptions are issued only after a licensed clinician reviews your history.

© 2026 Veylo. All rights reserved.

Veylo

Veylo

Veylo